269
Participants
Start Date
February 29, 2012
Primary Completion Date
October 31, 2015
Study Completion Date
October 31, 2015
DVS SR
Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
Institute for Behavioral Medicine, LLC, Smyrna
Atlanta Center for Medical Research, Atlanta
Clinical Neuroscience Solutions, Inc., Orlando
Amedica Research Institute, Incorporated, Hialeah
Harmonex Neuroscience Research, Inc., Dothan
Hospital Aranda de la Parra, S.A. de C.V., León
Clinical Neuroscience Solutions, Inc., Memphis
Precise Research Centers, Flowood
North Star Medical Research, LLC, Middleburg Heights
Rogers Center for Research and Training, Incorporated, Milwaukee
St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles
CIT-Neuropsique, S.C., Monterrey
Psychiatric Associates, Overland Park
Lake Charles Clinical Trials,, Lake Charles
Arkansas Psychiatric Clinic Clinical Research Trials, P.A., Little Rock
IPS Research Company, Oklahoma City
Cutting Edge Research Group, Oklahoma City
Paradigm Research Professionals, LLC, Oklahoma City
Grayline Clinical Drug Trials, Witchita Falls
Focus & Balance, LLC, San Antonio
Children's Hospital Colorado, Aurora
Dedicated Clinical Research, Goodyear
University of Arizona Clinical and Translational Science Center (CATS), Tucson
University of Arizona College of Medicine Dept of Psychiatry, Tucson
Center for Psychiatry and Behavioral Medicine, Incorporated, Las Vegas
Behavioral Research Specialists, LLC, Glendale
Synergy Clinical Research Center, National City
Elite Clinical Trials, Incorporated, Wildomar
ATP Clinical Research, Incorporated, Costa Mesa
Neuropsychiatric Research Center of Orange County, Orange
Pacific Clinical Research Medical Group, Orange
Summit Research Network (Oregon), Incorporated, Portland
Northwest Clinical Research Center, Bellevue
Summit Research Network (Seattle) LLC, Seattle
Kolin Research Group, Winter Park
Lead Sponsor
Pfizer
INDUSTRY